Radiation-induced dermatitis is one of the most common side effects of radiotherapy.
history. It manifests as erythema, edema, pigment changes, hair loss, and dry and moist desquamation (Boström, Lindman, Swartling, Berne, & Bergh, 2001 ). Mild dermatitis is characterized by mild erythema or dry desquamation, which is typically the first clinically apparent skin changes after breast radiation within days to week of radiation exposure. Moderate dermatitis is characterized by painful, intense erythema, and edema that may progress to moist desquamation (Hymes, Strom, & Fife, 2006) . In severe dermatitis, there is a confluent moist desquamation that may lead to ulceration and secondary infections (Benderitter et al., 2010) . Radiodermatitis is painful and has a profound impact on the quality of life. It also can disrupt the treatment in severe cases with probable negative impact on outcome (Hymes et al., 2006) . Some general skin care measures such as sun exposure avoidance, skin washing with lukewarm water and mild soap, maintaining the irradiated area clean and dry, using water-based moistures, and wearing loose-fitting clothes and also application of topical steroids are considered for radiodermatitis prevention (Campbell & Illingworth, 1992) . Moreover, several interventions are evaluated for prevention of radiodermatitis through anti-inflammatory, antioxidant, or antimicrobial activity, including sandalwood oil and turmeric-based cream, Aloe vera, trolamine (tri ethanolamine), sucralfate, or hyaluronic acid and calendula in limited number of trials. However, large controlled trials evaluating their efficacy are lacking (Wickline, 2004) .
Radiodermatitis initiates with irreversible double-strand breaks in DNA of basal keratinocytes, stem cells in the hair follicles, and melanocytes by production of reactive oxygen species (ROS) and short-lived free radicals. The transendothelial migration of leukocytes and other immune cells from circulation to irradiated skin is the hallmark of radiation-induced skin injury. Thereafter, increased level of proinflammatory cytokines like interleukin (IL)-1, IL-6, and IL-8 and tumor necrosis factor (TNF)-α leads to inflammatory response and damage (Kole, Kole, & Moran, 2017) . Increased levels of IL-1 and TNF-α have been shown to stimulate the production of metalloproteases causing degradation of dermal components and disruption of the basal cell layer (Amber, Shiman, & Badiavas, 2014) . Milk thistle (Silybum marianum L.), belongs to Asteraceae family, is a well-known herb for its hepatoprotective effects. Its active component is a mixture of various flavonolignans called silymarin (Gabr, Ghareeb, El Shabrawi, Smetanska, & Bekheet, 2016) , which contains around 50% silybin, 20% silychristin, 10% silydianin, 5% isosilychristin, and between 10% and 30% unidentified fractions such as polymeric and oxidized polyphenolic compounds (Zholobenko & Modriansky, 2014) . Silybin is the main component and is often considered to be the responsible substance for silymarin biological effects (Nencini, Giorgi, & Micheli, 2007) . Several animal and human studies have illustrated that silymarin increases the glutathione concentration and superoxide dismutase activity, resulting in antioxidant, free radical scavenging, and lipid peroxidation inhibitory effects. Besides, it shows immunomodulatory effect by increasing lymphocyte proliferation, interferon gamma (IFN-γ), IL-4, and IL-10 secretion by activated lymphocytes and suppression of T-cell activation by affecting nuclear factor kappa light chain enhancer of activated B cell (NF-κB) pathway. Furthermore, anti-inflammatory activity of silymarin has also been proposed. Inhibition of neutrophil migration and leukotrienes and prostaglandin formation by down regulation of cyclooxygenase-2 (cox-2) and lipoxygenase-5 (lox-5) enzymes are probable mechanisms of this action (Gharagozloo et al., 2010) . Based on these properties, silymarin oral and topical formulations were used for prevention of radiotherapy-and chemotherapy-induced adverse reactions such as nephrotoxicity induced by cisplatin (Shahbazi et al., 2015) , radiotherapy-induced mucositis (Elyasi, Hosseini, Niazi Moghadam, Aledavood, & Karimi, 2016) , and capecitabine-induced hand and foot syndrome (Elyasi, Shojaee, Allahyari, & Karimi, 2017) .
A nonrandomized observational study that was conducted on breast cancer patients with radiodermatitis showed that application of a silymarin-based cream (content 0.25%) delayed the development of radiodermatitis from 29 to 45 days and also limited the severity of 
| Study population
Patients with diagnosis of breast cancer who intended to be treated with a planned course of postmastectomy radiotherapy to the chest wall who completed the following criteria included in the study: age above 18 years and total radiation dose of 50 Gy. Exclusion criteria were severe infection requiring antibiotic therapy, dissatisfaction of patient, history of allergy to silymarin, history of autoimmune and connective tissue diseases, diabetes mellitus, skin inflammatory diseases (e.g., ectopic dermatitis), smoking, concomitant use of nonsteroidal anti-inflammatory drugs, corticosteroids, and other immunosuppressive or antioxidant medications.
| Ethics
The study protocol was approved by the local Ethics Committee of Mashhad University of Medical Sciences (IR.MUMS. REC.1395.27) and was registered at the Iranian Registry of Clinical Trials (IRCT2016110730760N1). All participants signed written consent forms.
| Study protocol
The eligible patients were randomly allocated in either medicine (silymarin) or placebo group. The herbal medicine intervention used in this trial was a dry extract of S. marianum (also known as milk thistle), which is registered for use as a natural health product in Iran and obtained from fruit (seed) of milk thistle. Treatment groups received silymarin gel 1% (produced by Goldaru Pharmaceutical Company, Isfahan, Iran) containing 80% active ingredient based on silymarin flavonolignans (including silybin, silychristin, silydianin, 2,3-dehydrosilybin, and 2,3-dihydrosilychristin) once daily. Half fingertip unit of gel was applied on the chest wall radiation field after treatment from the first day of radiotherapy and continued consecutively for 5 weeks. The placebo gels were produced identically by the same company, containing all ingredients of silymarin gel except silymarin and colored (with food coloring) to match it. All of the patients received 25-30 fractions of three-dimensional conformal adjuvant RT after mastectomy using 6-MV linear accelerator machine (5 days of the week, in 2 Gy per fraction and the mean total dose of 50 Gy, during the 5 weeks of follow up in the morning or the afternoon).
Patients were not allowed to receive any other medications for radiodermatitis prevention. In patients who experienced Grade 4 radiodermatitis, discontinuation of RT considered based on radiation oncologist opinion.
| Outcomes
Patients were examined by the pharmacist and the oncologist regarding the radiodermatitis occurrence at the beginning of RT and at weekly intervals for 5 weeks according to RTOG and National Cancer Institute Common Terminology Criteria for Adverse Reaction (NCI-CTCAE) version 4.0 radiodermatitis grading scale (Pires, Segreto, & Segreto, 2008 ; Common Terminology Criteria for Adverse Events V4.0 (CTCAE), 2013). The RTOG and NCI-CTCAE are the most commonly used grading systems, and they measure the severity of radiation dermatitis for erythema, desquamation, and ulceration (the mean score will range 0 to 4; Table 1 ).
Furthermore, during the study, patients were followed for drug administration compliance and adverse drug reactions. They were considered to be adherent to their treatment if they consumed one tube of drug or placebo gel (30 g) at the end of the third week.
| Sample size
Based on available data from the previous study that had evaluated the efficacy of topical silymarin in prevention of radiodermatitis, the frequency of radiodermatitis occurrence according to RTOG scale score in silymarin and placebo groups at the end of treatment course were 76.5% and 98%, respectively (Becker-Schiebe et al., 2011) .
Assuming α error of 5% and study power of 80% (β = 0.20), the sample size was 18 patients in each silymarin and placebo group according to the following formula:
For improving the study power, we rounded up the sample size to 20 patients in each group.
| Randomization and blinding
A computer generated random allocation sequence was produced.
Then block randomization of four patients was used to ensure balanced allocation of eligible patients in the control and intervention arms. Silymarin and placebo gel were filled in the tubes with same appearance that were marked with letter A (silymarin gel) or B (placebo gel) by Goldaru company and delivered to the pharmacologist, and he was the person who know which letter (A or B) refer to silymarin and which one to the placebo until the end of the study.
Each tube was filled with 30 g of silymarin or placebo gel which one tube was enough for a 3-week period. Patients who fulfilled the inclusion criteria were selected by oncologist, who assigned them to A or B group and gave them gel tubes, based on allocation sequence. Evaluation of patients during the radiotherapy regarding radiodermatitis occurrence was performed by the clinical oncologist and the pharmacy student. Data collection and analysis were carried out by the pharmacy student and the clinical pharmacist, respectively. None of the oncologist, the pharmacy student, the clinical pharmacist, and the patients were aware of group allocation.
| Statistical methods
Results have been shown as mean ± standard deviation or median (range) for continuous or discrete quantitative variables, respectively, and number (percentages) for nominal variables. Kolmogorov-Smirnov 
| RESULTS
Of the 50 screened patients, 45 subjects were eligible to be enrolled in the study according to the inclusion or exclusion criteria. Twenty patients completed the study in each group (Figure 1 ). All these patients received the same dose of radiation to the chest wall after mastectomy without interruption all over the study course. Forty patients with average age of 48 ± 10 years completed the study. All of them were adherent to silymarin or placebo gel during the 5-week follow-up. Baseline characteristics of patients in both groups are summarized in Table 2 . There were no significant differences between groups regarding these characteristics.
Most of the patients in silymarin group experienced Stages 2 and 3 of breast cancer (45% in each stage) and Stage 3 in placebo group (45%; p value = 0.59). Moreover, RTOG and CTCAE scores were zero for all patients in both groups at the beginning of the study. The median of RTOG and CTCAE radiodermatitis scores remained 0 in silymarin group at the end of the third week but increased to one in placebo group (Table 2) .
The NCI-CTCAE and RTOG scores were significantly lower in silymarin group at the end of the third to fifth weeks (p value < 0.05), but not at the end of the first 2 weeks, based on both per protocol and intention to treat analysis (Table 3) .
As it is obvious inTable 4, radiodermatitis development and progression have had a delay in the silymarin group comparing with the placebo group and 80% and 40% of patients in silymarin group remained asymptomatic at the end of the third and the fourth weeks, which was much higher than placebo group (45% and 5%, respectively). Also, despite the fact that all patients in treatment group experienced radiodermatitis at the end of the fifth week, none of them were more severe than Grade 1. But on the contrary, in placebo group, 40% of patients experienced Grade 2 and even one patient experienced Grade 3.
Comparing the RTOG and NCI-CTCAE scores in each group during the RT with Friedman test, the scores have increased significantly in a significance level set at p value < 0.005. Based on Table 5 , there was no significant difference between RTOG and NCI-CTCAE scores of patients in silymarin group in any two consecutive weeks. But in the placebo group, the difference was significant between the third and the fourth weeks (p = 0.004) and also the fourth and the fifth weeks (p = 0.004). So, it seems that despite the progressive trend of radiodermatitis in both groups during the radiotherapy course, silymarin may cause a delay in its incidence and also decelerate the radiodermatits progression especially after 3 weeks of application.
Silymarin and placebo gels tolerated well, and no adverse effects relevant to silymarin administration reported by the participants.
| DISCUSSION
Radiodermatitis is the most common adverse effect of breast cancer radiotherapy (Ho et al., 2018) . During radiotherapy, around 95% of patients develop some degree of inflammatory symptoms, such as erythema, dry or moist desquamation, edema, and ulcers. A severe radiodermatitis, for example, moist desquamation, ulcers, and skin fibrosis, may necessitate discontinuation of the radiotherapy, which may negatively influence the outcome and impair patients' quality of life (Amber et al., 2014) . The pathogenesis of radiodermatitis is rather complex and comprises a combination of radiation tissue injury followed by an inflammatory reaction. An erythematous skin reaction develops by an increased vascular permeability and vasodilation. This for prevention of radiation dermatitis (Lokkevik, 1996) . Topical steroids such as mometasone 0.1% and hydrocortisone have been evaluated for their anti-inflammatory properties, which suggested that low dose of corticosteroids may be beneficial in reducing itching and irritation in patients with radiodermatitis (Ho et al., 2018) . Nevertheless, long-term application of high potency topical steroids may cause skin thinning and atrophy, which may be problematic (Nikolaou, Syrigos, & Saif, 2016) . Moreover, steroids are contraindicated in the presence of infection as they could mask the signs and symptoms of infection and worsen it (Sitton, 1992) . S. marianum extract is a wellknown hepatoprotective agent for many years, but to the best of our knowledge, it is the first double-blinded randomized clinical trial evaluating its topical formulation efficacy in prevention of radiodermatitis. Antioxidant properties of silymarin have been proposed in numerous studies by increasing the cellular glutathione content, inhibition of lipid peroxidation, and acting as free radical and reactive oxygen species scavenger. Moreover, it could increase RNA and protein synthesis leading to faster repair of tissue injuries (Karimi, Vahabzadeh, Lari, Rashedinia, & Moshiri, 2011) . Besides, silymarin exerts immunomodulatory and anti-inflammatory properties by inhibiting T-cell proliferation through blockade of the activation of NF-κB pathways, inhibition of COX II enzyme, and reduction of inflammatory cytokines serum levels (e.g., IL-1, IL-6, IL-8, and TNF-α; Křen & Walterova, 2005) . It is reported that the skin tissue distribution of silibinin is low by oral administration. So its topical delivery via the skin may be capable of reaching enough pharmacological activity (Hung, Lin, Zhang, Chang, & Fang, 2010 results. It should be mentioned that at the end of the first week of RT, the RTOG and CTCAE scores were zero in all patients of both groups, which seems that we should not expect detectable radiodermatitis occurrence in first week of radiotherapy. None of patients in silymarin group experienced grades higher than one during RT in contrast to placebo group (eight patients with Grade 2 and one patient with Grade 3 radiodermatitis at the end of the fifth week). So it seems that silymarin could reduce the severity of radiodermatitis, and the difference between groups may even be more evident if we continued the follow-up or prescribe the silymarin gel before the beginning of the RT, like Becher-Schiebe et al. study. It also should be mentioned that the median RTOG and CTCAE scores had increasing trend in both placebo and silymarin group, and none of patients' grade of radiodermatitis reduced during follow-up period. Hence, it can be concluded that silymarin gel 1% application may just delay radiodermatitis occurrence and slow down its progression. However, it should be noted that due to lack of rigorous regulation, the need for the manufacturer of the nutraceutical to prove efficacy, safety, and quality of a marketed product is less strongly enforced than in the pharmaceutical sector. Therefore, many available products might be ineffective ( This study suffered from some limitations. First, the sample size of our study was small because of the strict inclusion and exclusion criteria.
Second, the follow-up period could be longer to evaluate the occurrence of the late manifestation of radiodermatitis. Finally, we just used silymarin 1% gel, and increasing the silymarin content of the gel may increase its efficacy in radiodermatitis prevention.
| CONCLUSION
This study showed that applying silymarin gel 1% once a day may reduce the severity of radiodermatitis and delay its occurrence in patients with breast cancer. Larger clinical studies with modified silymarin topical formulations with different silymarin content, for extended period of application particularly on supraclavicular region are recommended to confirm this potential role of silymarin. It should be noted that for improving the reliability of findings, future studies have to adhere to the Consolidated Standards of Reporting Trials reporting standards and ensure that appropriate methods of randomization, allocation, blinding, and withdrawals handling are used .
